Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1994-05-13
1998-06-02
Chambers, Jasemine C.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
4351723, 435 691, 4353201, A61K 4800
Patent
active
057595356
ABSTRACT:
The present invention is directed to a method for the treatment of neoplastic disease comprising administering to a mammal having a tumor a cellular immunogen comprising an allogeneic population of cells expressing S one or more cytoldnes and tumor associated antigens encoded by autologous genomic tumor DNA.
REFERENCES:
patent: 5674486 (1997-10-01), Sobol et al.
Ostrand-Rosenberg et al, Tumor Specific Immunity . . . , Int. J. Cancer. Supp. 6, 61-68 (1991.
Marshall, Science, 269:1050-1055, 1995.
Miller et al., FASEB J., 9:190-199, 1995.
Calver et al., TIG, 10(5): 174-179, 1994.
Hodgson, Exp. Opin. Ther. Pat., 5(5):459-468, 1995.
Nih "Report and Recommendations . . . ", Dec. 7, 1995, 1-40.
Blankenstein, T. et al., Tumor Suppression after Tumor Cell-targeted Tumor Necrosis Factor .alpha. Gene Transfer, J. Exp. Med.,173: 1047-1052 (1991).
Colombu, M. et al., Granulocyte Colony-stimulating Factor Gene Transfer Suppresses Tumorigenicity of a Murine Adenocarcinoma In Vivo, J. Exp. Med., 173: 889-897 (1991).
Dranoff, G. et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc. Natl. Acad. Sci. USA, 90: 3539-3543 (1993).
Fearon, E.R. et al., Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response, Cell, 60: 397-403 (1990).
Ferrantini, M. et al., .alpha.l-Interferon Gene Transfer into Metastatic Friend Leukemia Cells Abrogated Tumorigenicity in Immunocompetent Mice: Antitumor Therapy by Means of Interferon-producing Cells, Cancer Res., 53: 1107-1112 (1993).
Golumbek, P. et al., Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4, Science, 254: 713-716 (1991).
Hui, K.M. et al., Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene, J. Immunol., 143: 3825-3843 (1989).
Karp, S.E. et al., Cytokine Secretion by Genetically Modified Nonimmunogenic Murine Fibrosarcoma, J. Immunol., 150: 896-908 (1993).
Kim, T.S. et al., MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens, Cancer Immunol. Immunother., 38: 185-193 (1994).
Kim, T.S. et al., Independent pathways are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma associated antigens, J. Immunother., 14: 298-304 (1993).
Kim, T.S. et al., Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressiing melanoma assoicated antigens prolongs the survival of tumor-bearing mice, Int. J. Cancer, 55: 865-872 (1993).
Kim. T.S. et al., Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma associated antigens, Int. J. Cancer, 51: 283-289 (1992).
Ostrand-Rosenberg, S. et al., Tumor-specific immunity can be enhanced by transfection of the tumor cells with syngeneic MHC class II genes or allogeneic MHC class I genes, Int. J. Cancer, 6(suppl.): 61-68 (1991).
Pardoll, D.M., Cancer vaccines, Immunol. Today, 14(6): 310-316 (1993).
Pardoll, D.M., New strategies for active immunotherapy with genetically engineered tumor cells, Curr. Opin. Immunol., 4: 619-623 (1992).
Porgador, A. et al., Antimetastatic Vaccination of Tumor-Bearing Mice with Two Types of IFN-y Gene-Inserted Tumor Cells, J. Immunol., 150: 1458-1470 (1993).
Porgador, A. et al., Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells, Int. J. Cancer, 53: 471-477 (1993).
Porgador, A. et al., Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence against Parental Metastatic Cells, Cancer Res., 52: 3679-3686 (1992).
Rosenberg, S.A., The immunotherapy and gene therapy of cancer, J. Clin. Oncol., 10: 180-199 (1992).
Russell, S.J. et al., Decreased tumorigenicity of a transplantable sarcoma following transfer and expression of an IL-2 cDNA, Int. J. Cancer, 47: 244-251 (1991).
Weber, J.S. et al., Modulation of Murine Tumor Major Histocompatibility Antigens by Cytokines in Vivo and in vitro, Cancer Res., 48: 5818-5824 (1988).
Yamada, G. et al., Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity, EMBO J., 6: 2705-2709 (1987).
Zoller, M. et al., Interferon-Gamma Treatment of B16 Melanoma Cells: Opposing Effects for Non-Adaptive and Adaptive Immune Defense and its Reflection by Metastatic Spread, Int. J. Cancer, 41: 256-266 (1988).
Chambers Jasemine C.
Hauda Karen M.
Research Corporation Technologies Inc.
LandOfFree
Immunotherapeutic strategies for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapeutic strategies for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapeutic strategies for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456577